title: [Associations between Clinical Factors and Acute Renal Failure Due to Cisplatin Combination Chemotherapy for Lung Cancer].
abstract: In this study, we investigated the clinical factors associated with acute kidney injury (AKI) due to combination therapy with cisplatin (CDDP) for treating lung cancer. We classified cases according to the presence or absence of adequate hydration and magnesium(Mg)administered above the regulations of the registered regimen to evaluate the effect due to differences in hydration on AKI. We also investigated clinical factors before and after administration of CDDP in each case group, and examined their association with AKI. Seventy-four patients with lung cancer that were indicated for treatment with a CDDP combination regimen between December 2012 and April 2013 were studied. The patients whose conditions progressed to AKI of Bgrade 2 accounted for 0% (0/33) in the Mg administration group and 7.3%(3/41)in the Mg non-administration group. In particular, 2 cases of serious AKI (grade 4) were observed in the Mg non-administration without additional hydration group. When compared with other groups, a high antiemetic rate and favorable urine volume were observed in the Mg administration with additional hydration group. In the patients with AKI, many developed hyponatremia of Bgrade 3 within 1 week after administration of CDDP. Although Mg administration and ample hydration seem to be effective measures to deal with CDDP-caused AKI, comprehensive monitoring, including antiemesis therapy, after CDDP administration and correction of electrolytes is important.
authors.affiliation: 1Pharmaceutical Division, Niigata Prefectural Cancer Center Hospital.
authors.forename: Koki
authors.initials: K
authors.lastname: Yamashita
authors.forename: Masaki
authors.initials: M
authors.lastname: Yoshino
authors.forename: Naho
authors.initials: N
authors.lastname: Sasaki
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Tanaka
authors.forename: Maki
authors.initials: M
authors.lastname: Abe
authors.forename: Chiaki
authors.initials: C
authors.lastname: Tagawa
authors.forename: Fumiko
authors.initials: F
authors.lastname: Kawahara
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Kato
authors.forename: Mayumi
authors.initials: M
authors.lastname: Kaise
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tanaka
authors.forename: Takaaki
authors.initials: T
authors.lastname: Chou
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009997:Osmotic Pressure; D012189:Retrospective Studies
chemical_list: D002945:Cisplatin